Invention Grant
- Patent Title: Agent, uses and methods for treatment
-
Application No.: US17097457Application Date: 2020-11-13
-
Publication No.: US11548950B2Publication Date: 2023-01-10
- Inventor: Lars Christian Biilmann Rønn , Ibrahim John Malik , Jeffrey B. Stavenhagen , Søren Christensen , Jan Egebjerg , Arnout Gerritsen , Edward van den Brink , Paul Parren , Rob de Jong
- Applicant: H. Lundbeck A/S
- Applicant Address: DK Valby
- Assignee: H. Lundbeck A/S
- Current Assignee: H. Lundbeck A/S
- Current Assignee Address: DK Valby
- Agency: Wolf, Greenfield & Sacks, P.C.
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K51/10 ; C07K16/28 ; A61P25/28 ; A61K39/395 ; A61K39/00
Abstract:
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Public/Granted literature
- US20210269524A1 AGENT, USES AND METHODS FOR TREATMENT Public/Granted day:2021-09-02
Information query
